Interest of Proton Pump Inhibitors in Reducing the Occurrence of COVID-19: A Case-Control Study
How to cite: Blanc, F.; Waechter, C.; Vogel, T.; Schorr, B.; Demuynck, C.; Martin-Hunyadi, C.; Meyer, M.; Mutelica, D.; Bougaa, N.; Fafi-Kremer, S.; Calabrese, L.; Schmitt, E.; Imperiale, D.; Jehl, C.; Boussuge, A.; Suna, C.; Weill, F.; Matzinger, A.; Muller, C.; Karcher, P.; Kaltenbach, G.; Sauleau, E. Interest of Proton Pump Inhibitors in Reducing the Occurrence of COVID-19: A Case-Control Study. Preprints 2020, 2020050016. https://doi.org/10.20944/preprints202005.0016.v1 Blanc, F.; Waechter, C.; Vogel, T.; Schorr, B.; Demuynck, C.; Martin-Hunyadi, C.; Meyer, M.; Mutelica, D.; Bougaa, N.; Fafi-Kremer, S.; Calabrese, L.; Schmitt, E.; Imperiale, D.; Jehl, C.; Boussuge, A.; Suna, C.; Weill, F.; Matzinger, A.; Muller, C.; Karcher, P.; Kaltenbach, G.; Sauleau, E. Interest of Proton Pump Inhibitors in Reducing the Occurrence of COVID-19: A Case-Control Study. Preprints 2020, 2020050016. https://doi.org/10.20944/preprints202005.0016.v1
Abstract
Keywords
Subject
Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Comments (1)
We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.
Leave a public commentSend a private comment to the author(s)
Commenter: Bruno CHARPIAT
The commenter has declared there is no conflict of interests.
Price E. Could the severity of COVID-19 be increased by low gastric acidity?. Crit Care. 2020;24(1):456. Published 2020 Jul 22. doi:10.1186/s13054-020-03182-0 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7374651/
Almario CV, Chey WD, Spiegel BMR. Increased Risk of COVID-19 Among Users of Proton Pump Inhibitors [published online ahead of print, 2020 Aug 25]. Am J Gastroenterol. 2020;10.14309/ajg.0000000000000798. doi:10.14309/ajg.0000000000000798
Lee SW, Ha EK, Yeniova AÖ, et al. Severe clinical outcomes of COVID-19 associated with proton pump inhibitors: a nationwide cohort study with propensity score matching [published online ahead of print, 2020 Jul 30]. Gut. 2020;gutjnl-2020-322248. doi:10.1136/gutjnl-2020-322248
https://gut.bmj.com/content/gutjnl/early/2020/07/30/gutjnl-2020-322248.full.pdf
Luxenburger H, Sturm L, Biever P, et al. Treatment with proton pump inhibitors increases the risk of secondary infections and ARDS in hospitalized patients with COVID-19: coincidence or underestimated risk factor? [published online ahead of print, 2020 Jul 1]. J Intern Med. 2020;10.1111/joim.13121. doi:10.1111/joim.13121
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7361636/
Charpiat B, Bleyzac N, Tod M. Proton Pump Inhibitors are Risk Factors for Viral Infections: Even for COVID-19? [published online ahead of print, 2020 Aug 10]. Clin Drug Investig. 2020;1-3. doi:10.1007/s40261-020-00963-x
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7417108/